Scottish researchers discover how cancer cells cheat
death
By Jenny Marra, Head of Press 01382 344910 j.m.marra@dundee.ac.uk
1 July 2003
CANCER RESEARCH UK scientists in Scotland
have uncovered a key signalling mechanism that may sustain cancer cells in
the face of anti-cancer drugs, the prestigious journal Nature Cell Biology*
reveals today (Tuesday).
It could explain how cancer cells shut down
a cell suicide system normally used by the body to get rid of unhealthy, damaged
or old cells.
Researchers at the University of Dundee
believe that knowing exactly how cancer cells manage to override these signals
and stay alive will help overcome resistance to treatments such as chemotherapy
and radiotherapy, which work mainly by triggering cell suicide.
Cell suicide is one of the ways in which
the body rejuvenates itself and stays healthy. When a cell detects something
is wrong it sends a signal to the suicide machinery within the cell causing
it to commit suicide. But many cancer cells are able to block the signals
that tell them to die, depriving the body of one of its key defences against
the disease.
Encouraging these suicidal tendencies in
cancer cells is one of the main targets for cancer treatments.
The new research has found how a signalling
molecule called ERK blocks one of the major pathways to cell suicide. Researchers
discovered ERK causes an important chemical change in a molecule called caspase-9,
which is involved in kick-starting a chain of events leading to cell suicide.
ERK prevents caspase-9 from working and so allows cells to cheat death.
Cancer Research UK Senior Research Fellow
Dr Paul Clarke, who led the team at the University of Dundee, says: "Many
existing cancer treatments already work by promoting the chain of events leading
to cell suicide, and resistance to treatment with anti-cancer drugs could
be explained by survival signals from cancer cells overriding the drugs' effects.
So there is a great deal to be gained by learning how the pathways leading
to cell death actually work."
But while the findings pinpoint a mechanism
that prevents cell death, doctors can't simply block the signalling process
as it performs many important functions in normal cells.
Instead, treatments will need to take more
specific action. Scientists will try to alter the way in which death molecules
such as caspase-9 react to signalling molecules such as ERK, and so reopen
the route to cell suicide.
Dr Clarke says: "By targeting specific points
in the chain, we should be able to develop treatments that can overcome the
problems of drug resistance."
He adds: "The next step will be experiments
to block the actual molecular site where the signalling molecules interact
with caspase-9. If that works, then blocking the same interaction in patients
could prove an effective new tool against cancer."
Richard Sullivan, Cancer Research UK's Head
of Clinical Programmes, says: "Learning as much as possible about the mechanisms
controlling cell suicide will be essential for new targeted therapies."
"Also, many current cancer treatments kill
cancer cells by activating cell pathways that are not understood in great
detail. The more we learn about them, the more effective and less toxic we
can make cancer treatments."
Nature Cell Biology Volume 5 Issue 7 (pp 647-654) July
2003